Reversibility of End-Organ Dysfunction With VADs
since April 2012, which does not necessarily need previous HTx listing on the Japan Organ Transplant Network. The current condition for reimbursement at least requires the approval of the institutional review board on listing in the center for HTx, and is still based on the policy of a bridge to transplantation. As such, the big difference between here and there is that destination therapy (DT) has not yet been approved in Japan. In other words, only patients who have a likelihood of HTx listing (ie, "likely" BTC in INTERMACS), as well as those who are already listed, are regarded as candidates for continuousflow VADs in Japan. Therefore, it is useful to predict reversibility of end-organ function, especially when we plan to implant VADs as "likely" BTC. To the best of our knowledge, there has been no report that describes how to predict reversibility of end-organ function preoperatively. We here sought to construct a new scoring system that can predict reversibility of liver or renal function for optimal patient selection for VAD implantation.
Methods

Patient Population
We retrospectively researched 77 consecutive patients with stage D heart failure who had received LVADs between November 2002 and October 2011 and had been followed at the University of Tokyo Hospital. We excluded 8 patients because of insufficient data or death from a cause (eg, sepsis) other than multiple organ failure (MOF) within 6 months after LVAD implantation, and finally we enrolled 69 patients who had received a VAD (implantable continuous-flow VADs, 18; extracorporeal pulsatile VADs, 51) and were followed at least for 6 months after implantation unless deceased. We enrolled 10 patients who had died of MOF within 6 months after LVAD implantation. MOF was defined as a death because of multiend-organ dysfunction with >3.0 mg/dl of TB and/or Cre. Patients were all treated with standard medical therapy consisting of β-blockers, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, aldosterone antagonists, and diuretics as tolerated before implantation of the VAD. Cardiac resynchronization therapy with a defibrillator was also performed if indicated. Intra-aortic balloon pumping (IABP), extracorporeal membrane oxygenation (ECMO), continuous hemodiafiltration (CHDF), mechanical ventilation, or combinations of these was executed on the basis of physicians' decision before LVAD insertion. Some patients required a right VAD (RVAD) in addition to LVAD perioperatively. RVAD therapy included the implantation of an extracorporeal VAD to the right ventricle (RV) or right atrium and/or the temporary RV assist with ECMO. Written informed consent was given by the patients and/or their family before VAD implantation in all cases. The study protocol was approved by the Ethics Committee of Graduate School of Medicine, the University of Tokyo [application no. 779 (1)].
Variables Evaluated
Clinical data evaluated in this study included the patients' demographic data and the requirement for mechanical support such as ECMO, IABP, CHDF, and mechanical ventilation. All patients were classified based on INTERMACS, which stratifies patients into 7 profiles on the basis of clinical severity. 15 We assigned profile 1 to those who were supported by ECMO or were completely dependent on IABP. Patients who received elective IABP insertion to stabilize hemodynamics prior to planned VAD implantation were classified into profile 2 as we previously reported. 16, 17 Patients with VADs enrolled in our study were assigned to profile 1-3, except for 1 patient classified as profile 4 who had modifier A. 18 All preoperative laboratory data were obtained <24 h before the operation in patients without CHDF. In those with CHDF, laboratory data were obtained just before the introduction of CHDF. Postoperative laboratory data, including TB and Cre, were obtained at 1, 3, and 6 months after LVAD implantation. For the patients who died within 6 months after LVAD implantation, data obtained just before death were adopted. In the case of patients who had undergone CHDF before death, data before the introduction of CHDF were adopted. TB >1.5 mg/dl or Cre >1.5 mg/dl at 6 months after LVAD implantation or just before death was defined as persistent end-organ dysfunction. Preoperative duration of catecholamine infusion was assumed as the duration of end-organ dysfunction, and was counted from the date when patients became dependent on continuous infusion of intravenous catecholamine until the day of LVAD implantation.
Statistical Analysis
We performed statistical analyses with PASW Statistics 18 (SPSS Inc, Chicago, IL, USA) and JMP version 9.0 (SAS Institute Inc, Cary, NC, USA). Continuous variables are expressed as mean ± standard deviation and compared by unpaired t-test or Mann-Whitney test as appropriate. Categorical variables are expressed as percentages and compared by chi-square test or Fisher's exact test as appropriate. Univariable and multivariable analyses with a logistic regression model were performed to calculate adjusted odds ratio (OR) and 95% confidence intervals to assess each preoperative risk factor for persistent end-organ dysfunction after LVAD implantation. Variables that had significance (P<0.05) by univariable analysis were recruited into the multivariable analysis. Considering the results of both analyses, weighted scores were allocated to selected variables on the basis of OR from univariable analyses, and we constructed 2 scoring systems as the summation of scores. Receiver-operating characteristic (ROC) analysis for postoperative renal or liver dysfunction was carried out on the basis of both scores, and cutoff values were determined. Among the patients who survived at least 6 months after LVAD implantation, time-dependent changes in TB and Cre were compared by repeated analysis of variance. Probability was 2-tailed, with P<0.05 regarded as statistically significant.
Results
Baseline Characteristics of Enrolled Patients
We enrolled 69 patients who had received a VAD (pulsatile VAD: 51; continuous-flow VAD: 18) between November 2002 and October 2011 and had been followed for >6 months in our institute unless deceased. We included 10 patients (14.5%) who died of MOF within 6 months after VAD implantation. The baseline characteristics are shown in Table 2 depicts the univariable analysis of preoperative demographic and laboratory parameters for prolonged elevation of TB. There were increased odds in the patients with higher age (OR 1.068), lower serum albumin (OR 0.296), and higher preoperative TB (OR 1.056) (P<0.05 for each). The univariable analysis for the prediction of postoperative persistent renal dysfunction is shown in Table 3 . Higher age (OR 1.100) and higher preoperative Cre (OR 3.568) were significantly associated with renal dysfunction (P<0.05 for each). Preoperative need for mechanical support and continuous catecholamine infusion duration were not significant demographic predictors of postoperative end-organ dysfunction. According to the multivariable analysis, higher age (P=0.004) and higher preoperative TB (P=0.007) were independent risk factors associated with incomplete recovery of liver dysfunction (Table 4A) . Table 4B shows the multivariable analysis for insufficient reversal of renal dysfunction, by which we found that higher age (P=0.006) and higher preoperative Cre (P=0.042) were independently associated with persistent elevation of postoperative Cre levels. 
Logistic Analysis of Preoperative Parameters
New Scoring for Prediction of Reversibility of End-Organ Function With LVAD
We used 2 risk factors that were significant in the multivariable analyses, namely, preoperative TB or Cre, together with age, in our new scoring system to predict postoperative recovery of end-organ function. Weighted coefficients were assigned based on the ORs obtained from univariable analyses. The TB score for liver function was calculated by the formula, 1.5 × (0.1 × age) + 1.1 × (TB), and the Cre score for renal function was calculated as, 2.0 × (0.1 × age) + 3.6 × (Cre). We performed ROC analyses on these scores, and determined the cutoff values as 11.0 points for the TB score (sensitivity, 0.833; specificity, 0.847) and 14.1 points for the Cre score (sensitivity, 0.917; specificity, 0.772) to give the best predictability (Figure 1) . The area under the curve (AUCs) was 0.794 for the TB score and 0.839 for the Cre score. Figure 2A depicts the relationship between age and TB among all patients with LVADs, and the cutoff line obtained from the formula is shown. The relationship between age and Cre is shown in Figure 2B in the same manner.
Stratification of Postoperative TB and Cre Level by Each Score
We classified the patients who survived at least 6 months after LVAD implantation into 2 strata according to the cutoff values of the TB and Cre scores. Patients in the high-risk stratum had higher levels of TB (TB score >11.0) than those in the low-risk stratum (TB score <11.0) during the study period by repeated analysis of variance (P<0.05) and TB levels 6 months after LVAD implantation were higher compared with those Cre levels in the high-risk stratum (Cre score <14.1) remained at the higher levels during the study period that were demonstrated by repeated analysis of variance (P<0.05), and Cre levels at 6 months after LVAD implantation were also higher compared with those assigned to the low-risk stratum (Cre score >14.1) (1.23±0.41 vs. 0.73±0.22, P<0.001). The Cre levels at 6 months after LVAD implantation were as high as those at 3 months (1.23±0.41 vs. 1.109±0.49, P=0.684) ( Figure 3A) .
We used the same analyses separately for patients with continuous-flow VADs and pulsatile VADs. Both the TB and Cre levels of the high-risk stratum (TB score >11.0 and Cre score >14.1) remained at higher levels during the study period that were demonstrated by repeated analysis of variance in both the continuous-flow VAD group and pulsatile VAD group (P<0.05), and we did not observe any significances between the 2 types of VADs in terms of the recovery pattern of end-organ function (Figures 3B,C) . Figure 4A depicts the Kaplan-Meier survival curves for the low-risk (TB score <11.0) and high-risk (TB score >11.0) strata. The 6-month mortality from MOF was significantly different between the 2 strata (94.4% and 58.8%, respectively) with log-rank test (P<0.001). We also performed Kaplan-Meier analyses for the Cre score, and the 6-month survival was significantly different between low-risk (Cre score <14.1) and highrisk (Cre score >14.1) strata (91.3% and 73.9%, respectively) with log-rank test (P=0.038) ( Figure 4B ). We then classified the patients into 3 strata according to the combination of both scores: low (TB score <11.0), intermediate (TB score >11.0 but Cre score <14.1), and high (TB score >11.0 and Cre score >14.1) risk strata. Figure 4C depicts Kaplan-Meier survival curves for the 3 individual strata. The 6-month mortality from MOF was significantly different among the 3 strata (94.4%, 77.8%, and 16.7%, respectively) with log-rank test (all P<0.05).
Stratification of Survival by TB and Cre Scores
Discussion
Based on our logistic analyses of preoperative risk factors for persistent end-organ dysfunction after LVAD implantation, we constructed a risk scoring system that is calculated from the preoperative level of TB or Cre together with age. By assigning patients into low-and high-risk strata with cutoff values obtained from ROC analyses, both scores successfully stratified postoperative end-organ function during the 6 months after LVAD implantation. Furthermore, the combination of the 2 scores well predicted 6-month mortality from MOF.
In this study, we judged recovery of end-organ function at 6 months after LVAD implantation in most of the patients enrolled. Other previously published studies showed that TB or Cre stabilized by 6 months after LVAD implantation, even if its recovery was not sufficient. 9,10,12,19-22 Consistently, levels of TB and Cre were statistically indistinguishable between 3 and 6 months after LVAD implantation in our study as shown in Figure 3 . We also included data for patients who died of MOF within 6 months after LVAD implantation. These patients had an extreme form of irreversible end-organ dysfunction, and all of them had TB >1.5 mg/dl and/or Cre >1.5 mg/dl at the time of death.
Some authors have reported that 1.5 mg/dl of TB is a cutoff level to increased mortality after transplantation. 1, 6 As for renal function, post-transplantation mortality began to increase when patients' Cre increased over 1.5 mg/dl. 8 Considering these results, in this study we defined persistent end-organ dysfunction that might significantly affect the prognosis after HTx as TB or Cre level >1.5 mg/dl after LVAD implantation. International Society for Heart and Lung Transplantation guidelines recommend that irreversible renal dysfunction with estimated glomerular filtration rate (eGFR) <40 ml · min -1 · 1.73 m −2 should be considered as a relative contraindication for HTx because of its poor postoperative prognosis. 5 The index is calculated by age and Cre, similar to our Cre score. 23 We also executed an ROC analysis of preoperative eGFR, but the AUC for the prediction of persistent reduction of eGFR (ie, <40 ml · min -1 · 1.73 m −2 after 6 months of LVAD implantation or at the time of death within 6 months) was 0.707 (sensitivity, 0.539; specificity, 0.830 at the cutoff point, 43.4). Therefore, we preferred the Cre score because of its better predictability of postoperative persistent renal dysfunction.
It is a matter of debate whether the different mechanics of LVADs influence recovery of end-organ function. Some investigators have demonstrated that a continuous-flow VAD improves end-organ function as well as a pulsatile VAD, contrary to their concern that the reduced pulsatility with continuous-flow VAD may have detrimental effects on end-organ function. 12,19,20 Our study also showed no significant difference between pulsatile and continuous-flow VADs in their effects on end-organ functional recovery. The reduced pulsatility may not be problematic for end-organ function as long as sufficient flow is maintained. In terms of VAD flow, continuous-flow VADs usually have the advantage over pulsatile VADs of accommodating incremental preload, because the latter have a fixed output.
Several authors have previously demonstrated that patients with RV failure have significantly higher mortality after VAD implantation. 17,24, 25 In the present study, 4 of 8 BiVAD patients died because of MOF within 6 months. Impaired systemic circulation and/or congestive end-organ dysfunction because of severe biventricular failure leads to MOF, which is often refractory even to BiVAD support. In fact, hepatic failure persisted in 4 BiVAD patients (50%), and renal dysfunction persisted in 3 BiVAD patients (38%).
We demonstrated that age was another independent determinant for persistent end-organ dysfunction among patients with VADs. It is well known that there is impaired recovery of renal function after acute kidney injury especially in aged individuals. 26 Better recovery from fulminant hepatitis is ob- Figure 4 . Kaplan-Meier survival curves corresponding to each serum total bilirubin (TB) score stratum (A), serum creatinine (Cre) score stratum (B), and combination of both scores (C) among the overall patients after left ventricular assist device implantation. *P<0.05 by log-rank test. Reversibility of End-Organ Dysfunction With VADs served in younger patients. 27 From these observations, the general principle emerges that it is more difficult for elderly patients to recover from end-organ dysfunction. Figure 2 shows that elderly patients consistently had a higher probability of persistent end-organ dysfunction even if their levels of TB or Cre were not as high as those of younger patients. Accordingly, when we aim to bridge to transplantation in aged population, an earlier decision to implant a VAD is needed to avoid persistent postoperative end-organ dysfunction.
Recently, DT has been approved in Europe and United States as an option to VAD therapy for those who are ineligible to HTx because of their higher age and/or irreversible end-organ impairment. 28, 29 Our scoring system consists of the patient's age and the level of TB or Cre that represents end-organ function. BTC is classified into "likely", "moderately likely", and "unlikely" based on the possibility of future HTx listing. According to INTERMACS, BTC has been the major strategy for VAD implantation, 14 but some BTC patients have not recovered sufficiently to meet the criteria for HTx listing. DT is a safety net for such patients, which is why BTC has become popular to date. Meanwhile, DT is not yet been approved in Japan, and therefore we still hesitate to implant continuousflow VADs in those whom end-organ dysfunction is "unlikely" to recover after VAD therapy. We believe that our scoring system is useful for judging preoperatively whether recovery of end-organ dysfunction is "likely" or "unlikely" after VAD implantation. In addition, the BTC strategy in "likely" patients may secure a better prognosis after HTx because we can expect better end-organ function before HTx.
As many studies previously reported, preoperative endorgan dysfunction and higher age are associated with early to mid-term mortality with VADs. 16,30-32 In the present study, among the 10 patients who died of MOF within 6 months after LVAD implantation, 7 had a TB score >11.0 and 5 had a Cre score >14.1. Among 12 patients whose postoperative TB was >1.5 mg/dl, only 2 survived more than 6 months after LVAD implantation. Among 12 patients whose postoperative Cre was >1.5 mg/dl, 4 survived for more than 6 months. The combination of both scores was able to stratify patients' survival into 3 strata, coincidentally those of BTC: the low-risk stratum (TB score <11.0) suggests "likely" to bridge to HTx; the intermediate-risk stratum (TB score >11.0 but Cre score <14.1) may be "moderately" likely to be listed for HTx; and the high-risk stratum (TB score >1.0 and Cre score >14.1) indicates "unlikely" to bridge to HTx.
Study Limitations
We acknowledge that our study has several limitations. This study was conducted retrospectively in a single center, and consequently included a limited number of patients. Our scoring system should be also analyzed prospectively for its predictability of end-organ dysfunction after LVAD implantation. We substituted preoperative catecholamine infusion duration for length of end-organ dysfunction because it was difficult to exactly define the duration of end-organ dysfunction. Prolonged catecholamine infusion is often associated with right-sided heart failure by venous congestion, which can result in hepatic and/or renal dysfunction. 33 However, there might be some discrepancy between the duration of catecholamine infusion and end-organ dysfunction in this study. It may be difficult for high TB and Cre levels to recover if end-organ dysfunction is sustained for a long period Continuous-flow LVADs have only been available in Japan since April 2011 and we could only enroll 18 patients who received continuous-flow VADs. The worldwide trend is definitely toward continuous-flow VADs, and we may need additional data of patients who receive continuous-flow VADs to construct a more useful scoring system. We adopted ORs obtained from univariable analyses as coefficients of the formulae of the scoring system, because the formulae constructed from the results of multivariable analyses did not fit well in elderly patients.
Conclusions
In conclusion, TB and Cre scores that consist of preoperative bilirubin or creatinine levels adjusted by the patient's age can be excellent predictors of prolonged liver or renal dysfunction 6 months after LVAD implantation. Such information would be useful when considering the best indication for BTC or DT.
